TransPharma Medical Ltd. Announces Successful Completion of a Phase 1b Clinical Trial of ViaDor-GLP1 Agonist Indicated for the Treatment of Type II Diabetes

Published: Feb 22, 2011

LOD, Israel--(BUSINESS WIRE)--TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1b trial of ViaDor-GLP1 agonist, which is being developed for the treatment of diabetes mellitus type II.

Back to news